These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29026947)

  • 1. PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.
    Gallamini A; Meignan M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):1-3. PubMed ID: 29026947
    [No Abstract]   [Full Text] [Related]  

  • 2. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010.
    Gallamini A; O'Doherty M
    Leuk Lymphoma; 2011 Apr; 52(4):583-6. PubMed ID: 21438829
    [No Abstract]   [Full Text] [Related]  

  • 3. Report on the First International Workshop on Interim-PET-Scan in Lymphoma.
    Meignan M; Gallamini A; Meignan M; Gallamini A; Haioun C
    Leuk Lymphoma; 2009 Aug; 50(8):1257-60. PubMed ID: 19544140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim PET in Hodgkin Lymphoma: Is It So Useless?
    Meignan M; Cottereau AS; Deau B; Kanoun S; Berriolo-Riedinger A; Casasnovas O
    J Nucl Med; 2017 Jul; 58(7):1180. PubMed ID: 28254870
    [No Abstract]   [Full Text] [Related]  

  • 5. Conference addresses potential flaws in peer review process.
    Baltic S
    J Natl Cancer Inst; 2001 Nov; 93(22):1679-80. PubMed ID: 11717323
    [No Abstract]   [Full Text] [Related]  

  • 6. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of testing PET-directed therapy in patients with Hodgkin lymphoma.
    Armitage JO
    Curr Hematol Malig Rep; 2011 Sep; 6(3):155-6. PubMed ID: 21670982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised response criteria for malignant lymphoma.
    Cheson BD; Pfistner B; Juweid ME; Gascoyne RD; Specht L; Horning SJ; Coiffier B; Fisher RI; Hagenbeek A; Zucca E; Rosen ST; Stroobants S; Lister TA; Hoppe RT; Dreyling M; Tobinai K; Vose JM; Connors JM; Federico M; Diehl V;
    J Clin Oncol; 2007 Feb; 25(5):579-86. PubMed ID: 17242396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extra scrutiny for industry funded trials.
    Rothman KJ; Evans S
    BMJ; 2005 Dec; 331(7529):1350-1. PubMed ID: 16339222
    [No Abstract]   [Full Text] [Related]  

  • 10. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
    Kobe C; Dietlein M; Fuchs M
    Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
    [No Abstract]   [Full Text] [Related]  

  • 11. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate.
    Levine JM; Weiner M; Kelly KM
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):667. PubMed ID: 17805052
    [No Abstract]   [Full Text] [Related]  

  • 12. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
    Kostakoglu L; Gallamini A
    J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.
    Gallamini A; Fiore F; Sorasio R; Meignan M
    Leuk Lymphoma; 2009 Nov; 50(11):1761-4. PubMed ID: 19883305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.
    Procházka V; Klugar M; Bachanova V; Klugarová J; Tučková D; Papajík T
    BMJ Open; 2016 Aug; 6(8):e011729. PubMed ID: 27496236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?
    Hutchings M
    Leuk Lymphoma; 2011 Sep; 52(9):1615-6. PubMed ID: 21767106
    [No Abstract]   [Full Text] [Related]  

  • 17. Interim PET in lymphoma: a step towards standardization.
    Meignan M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1821-3. PubMed ID: 20652564
    [No Abstract]   [Full Text] [Related]  

  • 18. Positron emission tomography in the management of Hodgkin lymphoma.
    Connors JM
    Hematology Am Soc Hematol Educ Program; 2011; 2011():317-22. PubMed ID: 22160052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma.
    Kluge R; Kurch L; Georgi T; Metzger M
    Semin Nucl Med; 2017 May; 47(3):242-257. PubMed ID: 28417854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.